<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00243555</url>
  </required_header>
  <id_info>
    <org_study_id>2002H05183</org_study_id>
    <secondary_id>FP-2005-25</secondary_id>
    <nct_id>NCT00243555</nct_id>
  </id_info>
  <brief_title>Development of an Algorithm to Better Predict Clinical Responsiveness to Peanut</brief_title>
  <official_title>Molecular Analysis of Immuno-Regulatory Genes Expressed by Mononuclear Cells From Peanut Skin Test Positive Individuals With and Without a History of Peanut Ingestion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hamilton Health Sciences Corporation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Food Allergy Initiative</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AllerGen NCE Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>McMaster University</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to develop a tool to better predict clinical allergy to peanut,
      so that those who are skin test positive but non allergic will not have to unnecessarily
      avoid peanut, and those with true allergy can be diagnosed, possibly without oral ingestion
      challenge, and treated appropriately
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Peanut allergy occurs in about 1% of the population. Allergic reactions to peanuts and tree
      nuts account for the majority of fatal and near fatal food allergic reactions. Currently the
      only available treatment is complete avoidance of peanut. Despite avoidance, the majority of
      peanut allergic people will accidentally ingest peanut. Accurate diagnosis is critical, yet
      often problematic. Current diagnostic methods such as skin and blood tests cannot predict
      definitively who is allergic and can result in patients being falsely labeled. One such group
      is children who have never been exposed to peanut as a means of preventing allergy, yet have
      positive skin tests. The only means of definitively diagnosing this group is with an oral
      peanut challenge, a potentially risky procedure. Previous studies have demonstrated
      differences in certain genes and growth factors between peanut allergic and non-allergic
      individuals. The proposed study has 2 phases. The first phase, almost completed, examines
      expression of genes and growth factors in defined groups of peanut allergic and non-allergic
      individuals which should help distinguish between these groups. Peripheral blood mononuclear
      cells from each patient will be cultured and analyzed for a variety of growth factors and
      other immune molecules, including mRNA, thought to be important in allergy.

      The second phase of this study will involve feeding peanut to individuals with positive skin
      tests, who have never been peanut exposed. Their blood will be examined before and after the
      challenge using information from Part 1, and results will be correlated with their ability to
      tolerate peanut on feeding. This study should enable us to better predict who is truly peanut
      allergic.

      There are four groups of patients in this study. Group 1 consists of individuals who are
      allergic to peanut. This group of individuals will have a positive skin test to peanut and a
      previous allergi reaction to peanut. Group 2 consists of indivduals who have a positive skin
      test to peanut but who are able to ingest peanuts without problems. Group 3 consists of
      individuals who have a positive skin test to peanut but who have no known ingestion of peanut
      and who have avoided peanut lifelong for whatever reason (e.g. a strong family history of
      peanut allergy). Lastly, group 4 consists of control subjects who are negative to the peanut
      skin test and are able to tolerate peanut without problems.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2002</start_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Screening</primary_purpose>
    <observational_model>Defined Population</observational_model>
    <time_perspective>Cross-Sectional, Prospective</time_perspective>
  </study_design_info>
  <enrollment>60</enrollment>
  <condition>Peanut Hypersensitivity</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allergy skin testing</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>venepuncture</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  5 years of age and older

          -  Informed consent (Subject has provided an appropriately signed and dated informed
             consent. An appropriately signed and dated assent must be obtained from the parents or
             guardian if the subject is a child under 18 years of age.)

          -  Free of any clinically significant disease, such as uncontrolled asthma, which may
             interfere with study evaluations

        Group 1:

          -  skin test positive to peanut

          -  documented clinical history of peanut allergy. A documented clinical history may
             include symptoms such as hives,swelling of the mouth or tongue, throat closing
             sensation, shortness of breath, wheezing, lightheadedness, anaphylaxis.

        Group 2:

          -  Positive skin test to peanut

          -  History of being able to tolerate peanut exposure without problems

        Group 3:

          -  Positive skin test to peanut

          -  No known ingestion of peanut

        Group 4:

          -  Negative skin test to peanut

          -  Negative skin test to other food and environmental allergens

          -  Able to tolerate peanut exposure without problems

        Exclusion Criteria:

          -  Women who are pregnant or nursing

          -  use of antihistamines or decongestant therapy four days prior to clinic visit

          -  use of nasal or inhaled corticosteroid in the 1 month period prior to clinic visit

          -  use of non-steroidal anti-inflammatory drugs (NSAIDS) in the week prior to clinic
             visit

          -  Moderate or severe/ uncontrolled asthma (defined as the use of more than 4 puffs of
             ventolin per day, not including prophylactic medications prior to exercise)

          -  Symptomatic allergic rhinitis

          -  Patients who had an acute allergic reaction to food, drugs, and bee sting in the 1
             month period prior to clinic visit

          -  Use of an epi-pen during the past month

          -  respiratory infection one month prior to clinic visit

          -  immunotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan Waserman, MSc, MD, FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hamilton Health Sciences Corporation, McMaster Site</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrea Marin, MD</last_name>
    <phone>905-521-2100</phone>
    <phone_ext>75642</phone_ext>
  </overall_contact>
  <location>
    <facility>
      <name>Hamilton Health Sciences Corporation, McMaster Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie Townsend</last_name>
      <phone>905-525-9140</phone>
      <phone_ext>22465</phone_ext>
      <email>hsresadm@mcmaster.ca</email>
    </contact>
    <contact_backup>
      <last_name>Deidre L. Henne</last_name>
      <phone>905-521-2100</phone>
      <phone_ext>74595</phone_ext>
      <email>henne@hhsc.ca</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Heaton T, Rowe J, Turner S, Aalberse RC, de Klerk N, Suriyaarachchi D, Serralha M, Holt BJ, Hollams E, Yerkovich S, Holt K, Sly PD, Goldblatt J, Le Souef P, Holt PG. An immunoepidemiological approach to asthma: identification of in-vitro T-cell response patterns associated with different wheezing phenotypes in children. Lancet. 2005 Jan 8-14;365(9454):142-9.</citation>
    <PMID>15639296</PMID>
  </reference>
  <reference>
    <citation>Turcanu V, Maleki SJ, Lack G. Characterization of lymphocyte responses to peanuts in normal children, peanut-allergic children, and allergic children who acquired tolerance to peanuts. J Clin Invest. 2003 Apr;111(7):1065-72.</citation>
    <PMID>12671056</PMID>
  </reference>
  <reference>
    <citation>Umetsu DT. Revising the immunological theories of asthma and allergy. Lancet. 2005 Jan 8-14;365(9454):98-100.</citation>
    <PMID>15639274</PMID>
  </reference>
  <reference>
    <citation>Kagan RS, Joseph L, Dufresne C, Gray-Donald K, Turnbull E, Pierre YS, Clarke AE. Prevalence of peanut allergy in primary-school children in Montreal, Canada. J Allergy Clin Immunol. 2003 Dec;112(6):1223-8.</citation>
    <PMID>14657887</PMID>
  </reference>
  <reference>
    <citation>Sampson HA. Update on food allergy. J Allergy Clin Immunol. 2004 May;113(5):805-19; quiz 820. Review.</citation>
    <PMID>15131561</PMID>
  </reference>
  <reference>
    <citation>Roberts G, Lack G. Diagnosing peanut allergy with skin prick and specific IgE testing. J Allergy Clin Immunol. 2005 Jun;115(6):1291-6.</citation>
    <PMID>15940149</PMID>
  </reference>
  <reference>
    <citation>van Odijk J, Ahlstedt S, Bengtsson U, Borres MP, Hulth√©n L. Double-blind placebo-controlled challenges for peanut allergy the efficiency of blinding procedures and the allergenic activity of peanut availability in the recipes. Allergy. 2005 May;60(5):602-5.</citation>
    <PMID>15813803</PMID>
  </reference>
  <verification_date>September 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2005</study_first_submitted>
  <study_first_submitted_qc>October 20, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2005</study_first_posted>
  <last_update_submitted>January 31, 2007</last_update_submitted>
  <last_update_submitted_qc>January 31, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 1, 2007</last_update_posted>
  <keyword>peanut hypersensitivity</keyword>
  <keyword>chemokines</keyword>
  <keyword>cytokines</keyword>
  <keyword>RNA,messenger</keyword>
  <keyword>monocytes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Peanut Hypersensitivity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

